MRD as an important prognostic factor

One of the main topics discussed in the podcast was the importance of minimal residual disease (MRD) in multiple myeloma. The speakers emphasized that MRD is a critical factor in determining prognosis, but there is still uncertainty about how to utilize this information effectively. They discussed the potential of MRD becoming a new endpoint in clinical trials and how it could lead to more targeted and cost-effective treatment strategies. However, they also acknowledged that regulatory authorities need convincing before MRD can be widely adopted as an endpoint.